Zobrazeno 1 - 5
of 5
pro vyhledávání: '"David Youngkin"'
Autor:
Tim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, Kevin Brown, Julie Dang, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei Wang, David Youngkin, Linda Liau, Neil Martin, Don Becker, Marvin Bergsneider, Albert Lai, Richard Green, Tom Oglesby, Michael Koleto, Jeff Trent, Steve Horvath, Paul S Mischel, Ingo K Mellinghoff, Charles L Sawyers
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Externí odkaz:
https://doaj.org/article/6c668f88ea25476fae7fe61ad50c3162
Autor:
Stuart MacGregor, Helen Schmid, Lauren G. Aoude, Judith Symmons, David Youngkin, Kevin M. Brown, Sonika Tyagi, Graham J. Mann, Susan L. Woods, Nicholas K. Hayward, Vanessa F. Bonazzi, K Holohan, Richard F. Kefford, Bruce K. Armstrong, Jane M. Palmer, Jeff Trent, Grant W. Montgomery, N. G. Martin, Ken Dutton-Regester, G Giles, John W Kelly, John L. Hopper, Ji Liu, E Gillanders, Mitchell S. Stark, J Aitken, Michael Gartside, Elizabeth A. Holland, David C. Whiteman, Christopher W. Schmidt, David L. Duffy, Chantelle Agha-Hamilton, Mark A. Jenkins, Anne E. Cust
Publikováno v:
Europe PubMed Central
Hereditary Cancer in Clinical Practice, Vol 10, Iss Suppl 2, p A46 (2012)
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 10, Iss Suppl 2, p A46 (2012)
Hereditary Cancer in Clinical Practice
Family and twin studies indicate that melanoma susceptibility has a strong genetic component. Very rarely, melanoma runs in families in which there is an inherited mutation in a single ‘high penetrance’ gene, but in the general population melanom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ce14cfafe6ad071086a3c60aeb0f207
https://doi.org/10.1186/1897-4287-10-s2-a46
https://doi.org/10.1186/1897-4287-10-s2-a46
Autor:
Donald Chow, Susan L. Woods, Natalie M. Niemi, Victoria Zismann, Jeffrey P. MacKeigan, Jonathan Ellis, Yuanqing Wu, Lauren G. Aoude, Richard A. Gibbs, Irene Newsham, Catherine M. Lanagan, Ken Dutton-Regester, Christopher W. Schmidt, Kevin M. Brown, Donna M. Muzny, Michael Gartside, Chris Sereduk, David Youngkin, Bradford R. Brooks, Mitchell S. Stark, Jeffrey M. Trent, Nanyun Tang, Hongwei Yin, Jeffrey S. Reid, Thomas Pollak, Nicholas K. Hayward, Vanessa F. Bonazzi, Sonika Tyagi, Bostjan Kobe, Jane M. Palmer
Publikováno v:
Nature genetics
We sequenced eight melanoma exomes to identify new somatic mutations in metastatic melanoma. Focusing on the mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) family, we found that 24% of melanoma cell lines have mutations in the protein-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d41db2fa74dbb2fc476205abb32c039
https://pubmed.ncbi.nlm.nih.gov/22197930
https://pubmed.ncbi.nlm.nih.gov/22197930
Autor:
Teli Hsueh, Tom Oglesby, Koji Yoshimoto, Charles L. Sawyers, Michael Koleto, Paul S. Mischel, Don Becker, Marvin Bergsneider, Steve Horvath, Yinan Chen, Jeff Trent, David Youngkin, Neil A. Martin, Julie Dang, Shaojun Zhu, Wei-wei Wang, Linda M. Liau, Timothy F. Cloughesy, Kevin M. Brown, Albert Lai, Richard M. Green, Phioanh L. Nghiemphu, Ingo K. Mellinghoff
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
PLoS Medicine
PLoS Medicine
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4217352ebb06379073eadc22e5259a6c
http://europepmc.org/articles/PMC2211560
http://europepmc.org/articles/PMC2211560
Autor:
David M. Wagner, Jicheng Hao, Jessica M. Girard, Jeffrey W. Touchman, Debbie S. Benitez, Maulik K. Shah, Stephen D. Mastrian, Erin A S Clark, Christopher J. Allender, David Youngkin, Paul Keim, Stephen M. Beckstrom-Sternberg, Amy J. Vogler, Raymond K. Auerbach
Publikováno v:
PLoS ONE
PLoS ONE, Vol 2, Iss 2, p e220 (2007)
PLoS ONE, Vol 2, Iss 2, p e220 (2007)
BackgroundYersinia pestis, the causative agent of plague, is responsible for some of the greatest epidemic scourges of mankind. It is widespread in the western United States, although it has only been present there for just over 100 years. As a resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99dc3389a7d6d9b4e5d1c691045a0be8
https://pubmed.ncbi.nlm.nih.gov/17311096
https://pubmed.ncbi.nlm.nih.gov/17311096